Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03005782 · ClinicalTrials.gov registry record · Phase 1
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 333
- Enrollment target
NCT03005782 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 333 participants.
The verdict
NCT03005782, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 333 participants
- Enrollment target
Study Summary
The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).
Interventions
- DRUG cemiplimab
- DRUG REGN3767
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2016-11-07 |
| Est. Completion | 2024-04-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03005782
The ClinicalTrials.gov registry entry for NCT03005782 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cemiplimab is the first listed.
NCT03005782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03005782 about?
NCT03005782 is a clinical study titled "Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers". The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary o...
What is the current status of trial NCT03005782?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 333 participants. The study started on 2016-11-07. Estimated completion is 2024-04-02.
What interventions are being tested in trial NCT03005782?
The interventions under investigation include: cemiplimab (DRUG), REGN3767 (DRUG).
Who is sponsoring clinical trial NCT03005782?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.